Sintx Technologies Appoints Ryan Elmore as President; CEO Eric Olson Retains Chairman Role

summarizeSummary

Sintx Technologies announced the appointment of Ryan Elmore as President, effective March 16, 2026, while current President Eric Olson will transition to solely Chairman and CEO. The new President brings extensive industry experience and a significant compensation package.

check_boxKey Events

• New President Appointed

  Ryan Elmore has been appointed President of Sintx Technologies, effective March 16, 2026. Mr. Elmore has over 20 years of leadership experience in the medical device and life sciences industries, including senior executive roles at Invibio.

• CEO Retains Chairman Role

  Eric Olson will cease serving as President but will continue in his roles as Chairman of the Board and Chief Executive Officer of the Company, ensuring leadership continuity.

• Executive Compensation Package Detailed

  Mr. Elmore's compensation includes an annual base salary of $375,000, a target annual cash bonus of 35% (guaranteed for the first year), a $100,000 sign-on bonus, and a restricted stock unit award with a grant date value of $300,000. He is also eligible for additional equity awards tied to international business milestones.

auto_awesomeAnalysis

Sintx Technologies has appointed Ryan Elmore as its new President, effective March 16, 2026, signaling a significant strengthening of its executive leadership. Mr. Elmore brings over two decades of experience in the medical device and life sciences industries, including senior roles at Invibio, which could be crucial for the company's strategic direction and international business expansion. While the compensation package for the new President is substantial, including a $375,000 base salary, a guaranteed annual bonus, a $100,000 sign-on bonus, and $300,000 in restricted stock units, it reflects the company's commitment to attracting experienced talent. CEO Eric Olson will continue to serve as Chairman and CEO, maintaining leadership continuity. This move suggests a focus on operational growth and market penetration, particularly in advanced biomaterials and medical device markets.